The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation

Immunological Reviews

Volumn 172, Issue , 1999, Pages 255-266

  Alfonso, Christopher ^a   Liljedahl, Monika ^a,b   Winqvist, Ola ^a,c   Surh, Charles D ^e   Peterson, Per A ^a   Fung Leung, Wai Ping ^a   Karlsson, Lars ^a,d  

^a R W Johnson Pharmaceutical Inst   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Amersham Biosciences   (Sweden)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA D ANTIGEN; IMMUNOGLOBULIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE RECEPTOR;

ANTIGEN BINDING; ANTIGEN PRESENTATION; B LYMPHOCYTE; ENDOPLASMIC RETICULUM; ENDOSOME; HELPER CELL; HUMAN; LYSOSOME; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; REVIEW; T LYMPHOCYTE;

EID: 0033405583     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01370.x     Document Type: Review

References (74)

1. 1. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-850.
2. 2. Marks MS, Blum JS, Cresswell P. Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens. J Cell Biol 1990;111:839-855.
3. 3. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991;354:392-394.
4. 4. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 1994;180:1107-1113.
5. 5. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-462.
6. 6. Park SJ, Sadegh-Nasseri S, Wiley DC. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1. Proc Natl Acad Sci USA 1995;92:11289-11293.
7. 7. Jasanoff A, Song S, Dinner AR, Wagner G, Wiley DC. One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules. Immunity 1999;10:761-768.
8. 8. Anderson MS, Miller J. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1992;89:2282-2286.
9. 9. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990;345:615-618.
10. 10. Teyton L, et al. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990:348:39-44.
11. 11. Busch R, Cloutier I, Sekaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996;15:418-428.
12. 12. Aichinger G, et al. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J Biol Chem 1997;272:29127-29136.
13. 13. Lotteau V, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600-605.
14. 14. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-716.
15. 15. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988;85:3975-3979.
16. 16. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance αβ heterodimers in endosomes. EMBO J 1992;11:411-416.
17. 17. Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 1994;91:2171-2175.
18. 18. Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994;1:763-774.
19. 19. Riese RJ, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4:357-366.
20. 20. Nakagawa TY, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-217.
21. 21. Shi G-P, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999;10:197-206.
22. 22. Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 1991;88:3150-3154.
23. 23. Roche PA, Teletski CL, Karp DR, Pinet V, Bakke O, Long EO. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR. EMBO J 1992;11:2841-2847.
24. 24. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155-165.
25. 25. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995;3:197-205.
26. 26. Sloan VS, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
27. 27. Karlsson L, Peleraux A, Lindstedt R, Liljedahl M, Peterson PA. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 1994;266:1569-1573.
28. 28. Sanderson F, et al. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 1994;266:1566-1569.
29. 29. Pierre P, et al. HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity 1996;4:229-239.
30. 30. Fung-Leung W-P, et al. Antigen presentation and T cell development in H2-M deficient mice. Science 1996;271:1278-1281.
31. 31. Miyazaki T, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996;84:531-541.
32. 32. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-550.
33. 33. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol 1998;28:2605-2618.
34. 34. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990;343:71-74.
35. 35. Sette A, et al. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 1992;258:1801-1804.
36. 36. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992;360:474-477.
37. 37. Ceman S, Rudersdorf R, Long EO, Demars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol 1992;149:754-761.
38. 38. Denzin LK, Hammond C, Cresswell P HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 1996;184:2153-2165.
39. 39. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293-302.
40. 40. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15:6144-6154.
41. 41. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-620.
42. 42. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:77-82.
43. 43. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996;4:87-96.
44. 44. Tonelle C, DeMars R, Long EO. DOβ: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J 1985;4:2839-2847.
45. 45. Wake CT, Flavell RA. Multiple mechanisms regulate the expression of murine immune response genes. Cell 1985;42:623-628.
46. 46. Karlsson L, Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual tissue distribution. Nature 1991;351:485-488.
47. 47. Liljedahl M, Kuwana T, Fung L, Wai P, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996;15:4817-4824.
48. 48. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol 1997;9:355-364.
49. 49. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996;15:4817-4824.
50. 50. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997;278:106-109.
51. 51. Van Ham SM, et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol 1997;7:950-957.
52. 52. Liljedahl M, et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998;8:233-243.
53. 53. Kropshofer H, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971-2981.
54. 54. Surh CD, et al. Two subsets of epithelial cells in the thymic medulla. J Exp Med 1992;176:495-505.
55. 55. Stern LJ, Wiley DC. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell 1992;68:465-477.
56. 56. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991;353:167-170.
57. 57. Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 1994;370:647-650.
58. 58. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 1998;161:3282-3291.
59. 59. Lindstedt R, Liljedahl M, Peleraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 1995;3:561-572.
60. 60. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995;131:351-369.
61. 61. Copier J, et al. Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB. J Immunol 1996;157:1017-1027.
62. 62. Copier J, Potter P, Sacks SH, Kelly AP. Multiple signals regulate the intracellular trafficking of HLA-DM in B-lymphoblastoid cells. Immunology 1998;93:505-510.
63. 63. Sandoval IV, Bakke O. Targeting of membrane proteins to endosomes and lysosomes. Trends Cell Biol 1994;4:292-297.
64. 64. Samaan A, Thibodeau J, Mahana W, Castellino F, Cazenave PA, Kindt TJ. Cellular distribution of a mixed MHC class II heterodimer between DR α and a chimeric DO β chain. Int Immunol 1999;11:99-111.
65. 65. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
66. 66. Morris P, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
67. 67. Jensen PE. Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH. J Exp Med 1991;174:1111-1120.
68. 68. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Crystal structure of mouse H2-M. Immunity 1998;9:385-393.
69. 69. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998;9:377-383.
70. 70. Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 1984;160:1102-1113.
71. 71. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-539.
72. 72. Accolla RS, Cina R, Montesoro E, Celada F. Antibody-mediated activation of genetically defective Escherichia coli β-galactosidases by monoclonal antibodies produced by somatic cell hybrids. Proc Natl Acad Sci USA 1981;78:2478-2482.
73. 73. Jemmerson R, Paterson Y. Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science 1986;232:1001-1004.
74. 74. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995;1815:1957-1963.